8-K filed Sep 14, 2026 at 08:59 ET
Phio Pharmaceuticals announced a key development milestone for its lead siRNA candidate PH-762, submitting a meeting request and comprehensive briefing package to the FDA to support a planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma, following the formal completion of the Phase 1b trial. Clinical supplies for the next study are expected in Q1 2027, and the nonclinical toxicology dosing phase has been completed. This is an early-stage regulatory step with no financial data or clinical results disclosed, making it a modestly positive but highly uncertain catalyst for a $12M market cap pre-revenue biotech.